EUVIMEDEUVIMED entdecken
Open Access

Practice viewpoints: AICD, who and when?

R J Sung, N-Y Chan

Heart Asia · 2009

DOI: 10.1136/ha.2009.000828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Heart Asia, 2009. Verfasst von R J Sung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Sciences, National Central University, Jhongli, Taoyuan, Taiwan; Division of Cardiovascular Medicine, Stanford University School of…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Automatic implantable cardioverter-defibrillator (AICD) is a costly but effective treatment modality for the prevention of sudden cardiac death (SCD). Causes of SCD are age-dependent, disease-specific and affected by racial/ethnic differences. Atherosclerotic heart disease (ASHD) is the most frequent underlying disease in individuals ≥35 years old. Available information suggests that Asians have a lower rate of SCD compared with African black individuals and Caucasians. Whether it is for secondary or for primary prevention, physicians should be educated to perform a thorough diagnostic work-up and be able to identify transient and/or reversible causes of lethal ventricular tachyarrhythmias such as acute myocardial infarction, residual ischaemia, electrolyte imbalance, adverse effect of drugs, valvular heart diseases, etc before contemplating AICD implantation. Correction of these reversible causes may avoid the necessity of AICD implantation. The status of left ventricular function is not sufficiently specific for guiding AICD implantation in ASHD patients after acute myocardial infarction. The urgent need is to develop better biological or physiological markers for risk stratification so that patients who would actually benefit from AICD implantation can be readily identified. Such an approach will make the use of AICD more cost-effective. Based on molecular genetic data obtained from patients with inherited structural cardiovascular diseases and malignant arrhythmogenic disorders in which the risk of SCD appears to be gene- and/or mutant-specific, a continuous search for genetic markers for better risk stratification is warranted in patients suffering from ASHD.

Autor:innen und Institutionen

  • Institute of Life Sciences, National Central University, Jhongli, Taoyuan, Taiwan; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Princess Margaret Hospital, Kowloon, Hong Kong, PR China.

Zitieren

APA

Sung, R. J., & Chan, N. Y. (2009). Practice viewpoints: AICD, who and when?. Heart Asia. https://doi.org/10.1136/ha.2009.000828

Vancouver

Sung RJ, Chan NY. Practice viewpoints: AICD, who and when?. Heart Asia. 2009. doi:10.1136/ha.2009.000828

BibTeX
@article{Sung2009,
  author = {Sung, R J and Chan, N-Y},
  title = {Practice viewpoints: AICD, who and when?},
  journal = {Heart Asia},
  year = {2009},
  doi = {10.1136/ha.2009.000828}
}
Kostenlos starten →